Adocia Sa · EURONEXT:ADOC
Adocia Sa — Investor Presentation (September 2024)
41 slides from Adocia Sa's investor presentation, September 2024
Slide 1: Corporate Presentation September 2024
Corporate Presentation September 2024
Slide 2: Forward-looking statements
Forward-looking statements This corporate presentation (the “Presentation”) has been prepared by ADOCIA S.A. (the “Company” and, together with its subsidiary, the “Group”) and is provided for information purposes only. It is not for promotional use. References herein to the Presentation shall mean a
Slide 3: Adocia at a glance
Adocia at a glance Mission: Development of innovative formulations of approved peptides and novel cell 1 therapy approaches for diabetes and obesity Business model: Licensing-out/Partnering our products and technologies after proof-of-concept 2 in animal and/or human model 2 partnerships with large
Slide 4: Highly experienced management team
Highly experienced management team Olivier Soula Mathieu-William Gilbert PhD, MBA CEO Chief Operating Officer Co-founder Chief Financial Officer Gérard Soula Rosy Eloy Jérémy Benattar PhD, MBA PharmD, Eng MD President & CBO Head of Marketing Strategy Chief Medical Officer Co-founder • Co-founded by
Slide 5: Business Strategy: solid partnerships and promising projects
Business Strategy: solid partnerships and promising projects Partnerships: BC Lispro M1Pram Agreements with insulin Future milestones ($30M) + royalties Exclusive negotiation rights in view of leader Pharma a global partnership Proprietary Products to be licensed: BC Lispro AdoShell Islets AdOral Se
Slide 6: A diversified specialty products pipeline
A diversified specialty products pipeline Preclinic Phase 1 Phase 2 Phase 3 Status / Upcoming milestones Partner Diabetes Phase 3 in China ongoing BC Lispro Ultra-Rapid Insulin Phase 3 in USA and Europe ready to start* Asia & other territories Insulins Combination BC Combo Phases 1 completed Long ac
Slide 7: Partnering models based on proprietary technology platforms with strong IP strategy
Adocia’s partnering models are based on proprietary technology platforms with strong IP strategy BioChaperone® AdOral® AdoShell® AdoGel® • Pharmaceutical excipient • Pharmaceutical excipient • Hydrogel scaffold • Biomaterial • Forms a complex with • Enhances peptides oral route • Cells encapsulation
Slide 8: Diabetes and Obesity: worldwide chronic pandemics
Diabetes and Obesity: worldwide chronic pandemics 537 million people live with diabetes1 Diabetes is closely linked to obesity 1 in 11 • In the US, 65% of adults with type 13 diabetes, and 85% of type 24 are overweight or obese, making DIABESITY a new pandemic 1.9 billion are overweight or obese2 IN
Slide 9: Proprietary specialty products based on approved drugs
Proprietary specialty products based on approved drugs 9 9
Slide 10: BioChaperone Lispro
BioChaperone® Lispro Ultra-Rapid Acting Insulin for a tighter glycemic control 10 10
Slide 11: BC Lispro has competitive advantages in the Ultra-Rapid Insulin class
BC Lispro has competitive advantages in the Ultra-Rapid Insulin class Post-meal glycaemia in T1D • Better efficacy profile for less hyperglycemia and less hypoglycemia (“Faster-in” / “Faster- out”) vs. comparators AUC0-2h: -61%* • Good tolerance for optimized daily use • Range of strengths (U100 & U
Slide 12: BC Lispro in phase 3 program in China with Tonghua Dongbao
BC Lispro in phase 3 program in China with Tonghua Dongbao Market • Insulin and analogs in China: c. $4 billion Partnership with Tonghua Dongbao (2018) • Licensed for development & commercialization for China and other Asian territories2: • $10m upfront • $ 5m milestone - 1st patient on the Phase 3
Slide 13: BC Combo, glargine-lispro premix
BC Combo, glargine-lispro premix The best insulin premix 13 13
Slide 14: BC Combo, a unique combination of glargine and lispro
BC Combo, a unique combination of glargine and lispro, the gold standards of basal and prandial insulins BioChaperone® Combo 1 product Once or twice a day U200 fixed ratio (150 U/mL glargine - 50 U/mL lispro) Simple Less hyperglycemia Affordable Limited number of injections Less hypoglycemia
Slide 15: M1Pram Insulin & Amylin analogs combination
M1Pram Insulin & Amylin analogs combination Breakthrough treatment to address the unmet medical need of overweight patients living with diabetes 15 15
Slide 16: Agreement with Sanofi on M1Pram
Agreement with Sanofi on M1Pram On July 5, 2023, • Adocia received €10m payment from Sanofi in exchange of an exclusive negotiation right on M1Pram • Sanofi commitment will contribute to accelerate M1Pram clinical development • Sanofi agreement covers any programs related to insulin / pramlintide co
Slide 17: M1Pram, a bi-hormonal therapy to treat people with obesity and diabetes
M1Pram, a bi-hormonal therapy to treat people with obesity and diabetes Higher risk of co-morbidities Obesity Diabetes Amylin Analog Insulin Analog Pramlintide M1 To control weight To control glycemia Insulin causes weight gain Obesity is a main concern for patients under intensive insulin therapy,
Slide 18: Amylin is missing in people with insulin-dependent diabetes
Amylin is missing in people with insulin-dependent diabetes, and it contributes to diabetes dysregulations Meal Insulin Normal pattern Amylin exerts important physiological effects on Level of secretion metabolism and weight control (relative scale) Amylin Glucagon 1. Activates amylin receptors in d
Slide 19: M1Pram reduces body weight with high efficacy in T1D with obesity
M1Pram reduces body weight with high efficacy in T1D with obesity CT041 : Phase 2 study – M1Pram vs. lispro (Humalog®) - type 1 diabetes - 16 weeks ambulatory Body Weight Change from Baseline to Week 16 All patients BMI ≥ 25 kg/m² BMI ≥ 30 kg/m2 (p value = 0.001) (post hoc, p value = 0.03) Mean +/-
Slide 20: Body weight loss with M1Pram comparable with insulin plus Semaglutide or Tirzepatide
Body weight loss with M1Pram in T1D is comparable with insulin plus Semaglutide or Tirzepatide treatment in T2D Change from baseline in body weight at W16 Semaglutide - 4.55 kg vs. - 1.08 kg Tirzepatide - 5.6 kg vs. + 0.4 Kg T2D taking basal insulin T2D taking glargine Mean BMI 32 kg/m2 [19-51] Mean
Slide 21: Maintained glycemic control, with 21% reduction in prandial insulin dose
Maintained glycemic control, with 21% reduction in prandial insulin dose Change from baseline* Mean (SD) P-value M1Pram Lispro HbA1c (%) 0.14 (0.51) 0.10 (0.51) 0.81 (NS) Time-In-Range 70-180 mg/dL (%) -3.17 (8.76) -1.54 (8.87) 0.29 (NS) Prandial insulin dose (U/d) -5.97(6.18) -0.61(7.08) <0.001 Whi
Slide 22: Medical value of M1Pram is confirmed
Medical value of M1Pram is confirmed Significant weight loss demonstrated & satiety effect Glycemic control maintained, without increase of hypoglycemia Sparing effect on prandial insulin dose Product well tolerated and safe Easy-to-use: one product injected at mealtime Excellent patient
Slide 23: M1Pram generates high expectations from KOLs
M1Pram generates high expectations from KOLs “The phase 2 study of M1Pram shows that a single injection with “The glycemic results with M1Pram (P1b) are each meal is as easy to use and as efficient as Humalog for quite promising as is the observed weight loss, glycemic control without increasing the
Slide 24: AdoShell Islets
AdoShell® Islets Immunoprotective scaffold for islets of Langerhans transplantation to cure Type 1 Diabetes 24 24
Slide 25: AdoShell Islets: the promise of cell therapy without immunosuppression
AdoShell® Islets: the promise of cell therapy without immunosuppression Islet transplantation is already approved and practiced in clinic in several countries Large clinical application is restricted due to AEs of immunosuppressants, used to avoid rejection AdoShell Islets: Designed to overcome the
Slide 26: AdoShell, an immuno-protective scaffold for islets of Langerhans transplantation
AdoShell®, an immuno-protective scaffold for islets of Langerhans transplantation for diabetes Hydrogel Reagents Immuno-isolation AdoShell Islets Ab, T cells Large entities > 10 nm + Insulin secreting cells • 1st generation: islets of Langerhans from deceased donors Free diffusion • 2nd generation:
Slide 27: AdoShell: An ultra-thin, immuno-protective hydrogel film for cells encapsulation
AdoShell®: An ultra-thin, immuno-protective hydrogel film for cells encapsulation High water content for cell compatibility Immuno-isolating gel Ultra-thin aseptic film High cell density for miniaturization Biocompatible Mechanically resistant Implantable by mini-invasive surgery Retri
Slide 28: POC in diabetic rat: glycemia controlled during a 132-day study
POC in diabetic rat: glycemia controlled during a 132-day study without immunosuppressor 1. Transplantation of AdoShell containing allogenic islets in diabetic rat peritoneum at day 0 2. Explantation of the implant at day 132. Sacrifice of control group at day 35 Glycemia Body Weight Insulin Transpl
Slide 29: AdoShell provides a platform, opening to many cell therapy markets
AdoShell provides a platform, opening to many cell therapy markets • AdoShell scaffold displays key attributes enabling to progress towards new and more effective cell therapies: No need of immunosuppressors • No need of gene-editing strategy for immune-evasive iPSCs Safe and efficient cell engr
Slide 30: AdOral
AdOral® A promising technology for oral delivery of peptides 30 30
Slide 31: Only 5 peptide therapeutics approved for oral delivery in a growing market
Only 5 peptide therapeutics have been approved for oral delivery in a growing market dominated by injectable forms Global Peptide Therapeutics Market* ($) *mAb excluded from the analysis Cyclosporin 39 Billion 48 Billion 1.2 kDa Approved 1995 Voclosporin Octreotide 50 Desmopressin 1.2 kDa 1.0 kDa GL
Slide 32: AdOral: a promising technology for oral delivery of peptides
AdOral: a promising technology for oral delivery of peptides AdOral is a unique formulation based on a new type of permeation enhancer (PE) combined with peptide protection against degradation Technology patented until 2042 globally The technology has been validated with Semaglutide compared to Rybe
Slide 33: Semaglutide formulated with AdOral shows improved bioavailability in animal
Semaglutide formulated with AdOral has shown significantly improved bioavailability in animal Median Semaglutide 14mg PK Profile (N=10) 200 1, 181 180 1.5, 169.5 2, 164.5 160 3, 153.5 0.75, 149 140 5, 140.5 120 AdOral® semaglutide 100 2.5-fold higher median 80 Rybelsus® 0.75, 74.65 than Rybelsus® 1,
Slide 34: AdoGel
AdoGel® Long-acting drug delivery platform 34 34
Slide 35: AdoGel, a biomaterial for ultra long delivery of therapeutic agents
AdoGel, a biomaterial for ultra long delivery of therapeutic agents Adocia is developing a soft tissue-like biomaterial for sustained release of small molecules/biologics • Pharmaceutic forms • Implantable & Removable device • Injectable (in-situ forming gel) • Main properties Implantable device Inj
Slide 36: Sustained release of Levonorgestrel over 180 days in animal model
First application: sustained release of Levonorgestrel (LNG) over 180 days after SC administration in animal model Mean (±SE) PK profile Cumulative absorption No initial burst Pseudo-zero order AdoGel® Preclinical proof of concept is ongoing with LNG Additional showcase studies are also ongoing with
Slide 37: Financial & news flow
Financial & news flow ADOCIA f-
Slide 38: News flow
News flow BC Lispro AdoShell® Islets • In China (with partner THDB): Phase 3 ongoing • First-in-human study preparation in 2024 • Phase 3 completion expected H2 2024 • $10m milestones payment AdoGel® Sema • In USA/EU: Phase 3 ready to be launched • Preclinical Proof of Concept in 2024 under partneri
Slide 39: Key financials & shareholder information
Key financials & shareholder information As of June 30, 2024 Key financials features Shareholder ownership Market information Already received • Listed on Euronext Paris (ADOC) • €97m raised in direct offerings since • 15 million of outstanding shares Free float Soula inception 69,8% Family & • ADR
Slide 40: Summary
Summary • Adocia’s projects are based on 4 proprietary technologies: BioChaperone®, AdOral®, AdoShell®, AdoGel® • Adocia is seeking to license-out the assets from its well-advanced and diversified pipeline: • Key products in ongoing clinical trials: o BC Lispro: Phase 3 in China o BC Combo: positive
Slide 41: Thank you for your kind interest
Thank you for your kind interest 115 avenue Lacassagne 69003 Lyon – FRANCE Ph.:+33 4 72 610 610 contact@adocia.com